[1] Zhai M, Long J, Liu S, et al.The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017.Aging,2021, 13 (1): 279-300.
[2] Moon A M, Singal A G, Tapper E B.Contemporaryepidemiology of chronic liver disease and cirrhosis.Clina Gastroenterol Hepatol,2020, 18 (12): 2650-2666.
[3] Man L, Qun W Z, Lu Z, et al.Burden ofcirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990 2016: Findings from the global burden of disease study 2016.Biomed Environ Sci,2020, 33 (1): 1-10.
[4] Tsuchida T, Friedman S L.Mechanisms of hepatic stellate cell activation.Nat Rev Gastroenterol Hepatol,2017, 14 (7): 397-411.
[5] Higashi T, Friedman S L, Hoshida Y.Hepatic stellate cells as key target in liver fibrosis.Adv Drug Deliv Rev,2017, 121: 27-42.
[6] Kisseleva T, Brenner D.Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol,2021, 18 (3): 151-166.
[7] Machado M V, Michelotti G A, Pereira T D A, et al.Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.Gut,2015, 64 (7): 1148-1157.
[8] Xie G, Karaca G, Swiderska-Syn M, et al.Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice.Hepatology,2013, 58 (5): 1801-1813.
[9] Beaven S W, Wroblewski K, Wang J, et al.Liver Xreceptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease.Gastroenterology,2011, 140 (3): 1052-1062.
[10] Morán-Salvador E, Titos E, Rius B, et al.Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.J Hepatol,2013, 59 (5): 1045-1053.
[11] Liu X, Xu J, Rosenthal S, et al.Identification oflineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution.Gastroenterology,2020, 158 (6): 1728-1744,e1714.
[12] Parola M, Pinzani M.Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.Mol Asp Med,2019, 65: 37-55.
[13] Valenti L, Al-Serri A, Daly A K, et al.Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.Hepatology,2010, 51 (4): 1209-1217.
[14] Sun Y, Zhou J, Wang L, et al.New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.Hepatology,2017, 65 (5): 1438-1450.
[15] Bosch J, Abraldes J G, Berzigotti A, et al.The clinical use of HVPG measurements in chronic liver disease.Nat Rev Gastroenterol Hepatol,2009, 6 (10): 573-582.
[16] Chinese Society of Hepatology C M A, Chinese Society of Gastroenterology C M A, Chinese Society of Infectious Diseases C M A.Consensus on the diagnosis and treatment of hepatic fibrosis (2019).J Dig Dis,2020, 21 (3): 127-138.
[17] Lurie Y, Webb M, Cytter-Kuint R, et al.Non-invasive diagnosis of liver fibrosis and cirrhosis.World J Gastroenterol, 2015 (41): 17.
[18] Wai C T, Greenson J K, Fontana R J, et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology,2003, 38 (2): 518-526.
[19] Sterling R K, Lissen E, Clumeck N, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology,2006, 43 (6): 1317-1325.
[20] Imbert-Bismut F, Ratziu V, Pieroni L, et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet,2001, 357 (9262): 1069-1075.
[21] Forns X, Ampurdanès S, Llovet J M, et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology,2002, 36 (4): 986-992.
[22] Zhou K, Gao C-F, Zhao Y-P, et al.Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B.J Gastroenterol Hepatol,2010, 25 (9): 1569-1577.
[23] Hui A Y, Chan L Y, Wong W S, et al.Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.Am J Gastroenterol,2005, 100 (3): 616.
[24] Rosenberg W M C, Voelker M, Thiel R, et al.Serum markers detect the presence of liver fibrosis: A cohort study.Gastroenterology,2004, 127 (6): 1704-1713.
[25] Zeng M-D, Lu L-G, Mao Y-M, et al.Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model.Hepatology,2005, 42 (6): 1437-1445.
[26] Xu MY, Jia XF, Qu Y, et al.Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B.J Translat Med,2013, 11 (1): 234.
[27] Shen FF, Wang Y, Wang YF, et al.Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model.J Transl Med,2018, 16 (1): 166. |
